Yazar "Demirci, Ayşe" için listeleme
-
The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: A multicenter study
Akdeniz, Nadiye; Kaplan, Muhammet Ali; Uncu, Doğan; İnanç, Mevlüde; Kaya, Serap; Dane, Faysal; Küçüköner, Mehmet; Demirci, Ayşe; Bilici, Mehmet; Gök Durnalı, Ayşe; Koral, Lokman; Şendur, Mehmet Ali Nahit; Erol, Cihan; Türkmen, Esma; Ölmez, Ömer Fatih; Açıkgöz, Özgür; Laçin, Şahin; Şahinli, Hayriye; Urakçı, Zuhat; Işıkdoğan, Abdurrahman (Springer, 2021)Purpose We aim to compare the efficiency and toxicity of three different 5-fluorouracil (5-FU) administration types in 5-FU, leucovorin, and oxaliplatin (FOLFOX) combination treatment for adjuvant therapy in colorectal ... -
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study
Şenocak Taşçı, Elif; Kutlu, Yasin; Ölmez, Ömer Fatih; Mutlu, Arda Ulaş; Gündoğdu, Yasemin; Seyyar, Mustafa; Şahin, Elif; Çabuk, Devrim; Majidova, Nargiz; Uğurlu, İrem; Demirci, Ayşe; Aydın, Dinçer; Çavdar, Eyyüp; Bayram, Selami; Yıldırım, Nilgün; Karataş, Fatih; Karakurt Eryılmaz, Melek; Çağlayan, Dilek; Menekşe, Serkan; Kut, Engin; Arak, Hacı; Keser, Murat; Sunar, Veli; Perkin, Perihan; Şakalar, Teoman; Oyan, Başak; Sönmez, Özlem; Özer, Leyla; Yıldız, İbrahim (2024)Background: Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine is being used as standard ... -
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
Karacin, Cengiz; Öksüzoğlu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Baytemür, Naziyet Köse; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Göksu, Sema Sezgin; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah (BioMed Central Ltd, 2023)Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which ... -
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)
Karacin, Cengiz; Öksüzoğlu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Köse Baytemur, Naziyet; Yılmaz, Funda; Selvi, Oğuzhan; Hacıbekiroğlu, İlhan (BMC, 2023)Following publication of the original article [1], the authors reported an error in the author name of Enes Erul.